Variman Global Enterprises approves ₹191 crore Ecogenics share swap
Key highlights
- Variman Global approved a ₹190.995 crore share-swap acquisition of a 99.99% stake in Ecogenics Technologies and Systems Limited.
- The Ecogenics proposal involves issuing up to 41,07,42,006 Variman Global equity shares to five sellers.
- The preferential issue includes up to 1,67,32,245 equity shares and 3,90,00,000 convertible warrants.
- Reported gross proceeds are ₹12.314243925 crore, while full warrant conversion would take the issue value to about ₹25.91 crore.
powered by IRIS

On August 29, 2026, Variman Global Enterprises Limited approved a ₹190.995 crore share-swap acquisition of a 99.99% stake in Ecogenics Technologies and Systems Limited, alongside a preferential equity and warrant issue with a stated full-conversion value of about ₹25.91 crore.
Know Variman Global Enterprises inside out
Results, valuation, peers and who's buying, in one view.
What did Variman Global approve on August 29, 2026?
Variman Global approved two connected corporate proposals: the acquisition of Ecogenics Technologies and Systems Limited through a share swap and a capital raising plan through preferential equity shares and convertible warrants. The proposals were approved by the board on August 29, 2026.
The Ecogenics transaction is valued at ₹190.995 crore and involves the proposed acquisition of a 99.99% stake. Separately, the company approved the issue of up to 1,67,32,245 equity shares and up to 3,90,00,000 convertible warrants to promoters, promoter-group participants and non-promoter investors.
The two actions have different purposes and structures. The Ecogenics proposal uses newly issued shares as consideration for the stake acquisition, while the preferential issue is intended to provide funds for operations and growth, according to the company’s stated purpose.
How is the Ecogenics Technologies acquisition structured?
Variman Global plans to acquire 99.99% of Ecogenics through a share-swap transaction valued at ₹190.995 crore. The company has approved the issue of up to 41,07,42,006 equity shares to five sellers of Ecogenics shares as consideration for the proposed acquisition.
A share swap does not require the buyer to make the acquisition payment entirely in cash. Instead, sellers receive equity shares of the acquiring company under the approved terms. The disclosure identifies five Ecogenics sellers as recipients of the proposed Variman Global shares, but does not provide their names in the supplied information.
The transaction would significantly expand the number of Variman Global shares proposed for issuance. The provided information does not state a closing date for the acquisition or provide financial details of Ecogenics, including its revenue, profit, assets or business operations. It also does not disclose the final shareholding pattern after the proposed share issue.
What are the terms of Variman Global's preferential issue?
Variman Global approved up to 1,67,32,245 equity shares at ₹4.65 each and up to 3,90,00,000 convertible warrants linked to equity shares priced at ₹4.65 each. The stated value of the equity-share component is ₹7.780493925 crore, while the full value of the warrant component on conversion is ₹18.135 crore.
Together, the equity shares and warrants have a stated full-conversion value of ₹25.915493925 crore, commonly described in the disclosure as about ₹25.91 crore. The warrants can be converted into equity shares within 18 months from allotment. The company stated that amounts related to warrants not converted within the permitted period would be forfeited.
The funding announcement separately reports gross proceeds of ₹7.780493925 crore from the equity shares and ₹4.53375 crore from the warrants, for aggregate reported proceeds of ₹12.314243925 crore. The warrant proceeds reflect an issue price of ₹1.1625 per warrant, which is one-fourth of ₹4.65. This distinction explains why the reported immediate proceeds are lower than the full-conversion value of the warrant issue.
Got a follow-up? Ask IRIS
What does Variman Global's earlier warrant history show?
Variman Global has previously used preferential warrants for fundraising, and its disclosures show that conversion and subscription conditions have been material to the outcome of such issues. The board approved an issue of up to 2,39,25,000 convertible warrants at ₹20 per warrant in April 2023, but the in-principle application was withdrawn after proposed allottees did not bring the required upfront subscription amount within the prescribed period.
In March 2024, shareholders approved the issue of 6,90,30,000 convertible warrants at ₹20 per warrant, aggregating to ₹138.06 crore. The board subsequently allotted 2,69,80,000 warrants to non-promoters in May 2024 after receipt of the 25% upfront amount.
Those 2,69,80,000 warrants lapsed on November 10, 2025, because warrant holders did not exercise their conversion option within the stipulated 18-month period. Variman Global’s directors’ report states that the upfront amount paid on those warrants was forfeited under the terms of the issue. This history gives context to the 18-month conversion period and forfeiture condition attached to the latest warrants.
How could the proposals affect investors and the company's capital structure?
The proposals could materially change Variman Global's capital structure because both the Ecogenics share swap and the preferential issue involve the proposed issuance of equity shares. The acquisition alone involves up to 41,07,42,006 shares, while the capital raising plan includes up to 5,57,32,245 shares when the equity shares and warrants are considered together.
For investors, the reported funding figure needs to be read alongside the full-conversion value. The ₹12.314243925 crore figure represents the reported gross proceeds from the proposed equity shares and initial warrant subscription, whereas approximately ₹25.91 crore reflects the value if all approved warrants are converted at ₹4.65 per underlying share.
No share-price movement, market capitalisation impact or post-transaction ownership breakdown was provided in the supplied disclosures. The immediate market relevance is therefore centred on the proposed stake acquisition, the scale of potential share issuance, the funding terms and the future conversion decisions of warrant holders.
Conclusion
Variman Global has combined a proposed ₹190.995 crore share-swap acquisition of a 99.99% Ecogenics stake with a preferential equity and warrant issue valued at about ₹25.91 crore on full conversion. The immediate reported proceeds from the equity issue and warrant subscription are ₹12.314243925 crore, highlighting the difference between funds initially received and the eventual value of converted warrants.
Investors will need to watch the implementation of the Ecogenics acquisition, the issue and allotment of the proposed shares and warrants, and warrant conversions over the 18-month exercise period. The company’s earlier warrant issuances, including the lapse of 2,69,80,000 warrants in November 2025, make the subscription and conversion progress relevant to assessing the eventual capital structure.


